The Patent Finder

Terms ending in 2035

Chemocentryx, Inc.

Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,745,268PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 10,266,492PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 10,532,982PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 11,845,729PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 10,532,051Compositions and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor 9 (CCR9) and Anti-alpha4beta7 Integrin Blocking Antibodies
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 11,020,394Compositions and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor Type 9 (CCR9) and ANTI-ALPHA4BETA7 Integrin Blocking Antibodies
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 11,045,469Compositions and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor Type 9 (CCR9) and ANTI-ALPHA4BETA7 Integrin Blocking Antibodies
In force
 · High confidence
ChemoCentryx, Inc.In forceHigh confidence
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited